Sio Gene Therapies Inc. Is A Buy Small Cap Stock: Analysts marketingsentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketingsentinel.com Daily Mail and Mail on Sunday newspapers.
During the last session, Sio Gene Therapies Inc. (NASDAQ:SIOX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.75. At the end of the trading day, the stock’s price was $2.49, reflecting an intraday gain of 1.63% or $0.04. The 52-week high for the SIOX share is $5.74, that puts it down -130.52 from that peak though still a striking 25.3% gain since the share price plummeted to a 52-week low of $1.86. The company’s market capitalization is $144.27M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 625.18K shares over the past three months.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Sio Gene Therapies Inc (NASDAQ: SIOX) has announced new biomarker data from Phase 1/2 study of AXO-AAV-GM1, an adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis.
This new data will be presented at the American Society of Gene. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
(SIOX) - Sio Gene Therapies' GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.